Home>Topics>Companies>Watson Pharmaceuticals

Watson Pharmaceuticals WPI

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. New Morningstar Analyst Report for Perrigo Co PLC

      Stock Reports

      Fri, 5 Sep 2014

      Perrigo in 2006, previously led the pharmaceutical and technologies segment of Cardinal Health and was COO of Watson Pharmaceuticals (now called Actavis). In addition to Papa's dual role as CEO and chairman, the board also includes two

    2. Stockton is Bankrupt: Now What?


      Thu, 11 Apr 2013

      Report: Merck Analyst Report: Mylan Technologies MYL Analyst Report: Teva Pharmaceuticals Analyst Report: Watson Pharmaceuticals WPI Rethinking Title Insurer Moat, Risk Ratings Analyst Jim Ryan reduced the moat rating and increased the risk

    3. Actavis Previews Financial Results and Highlights Plan for Future Growth


      Fri, 25 Jan 2013

      Now trading under its official new name, Actavis ACT (formerly Watson Pharmaceuticals ) highlighted its long-term growth strategy and presented expectations for the current quarter and upcoming 2013 results at its

    4. New Morningstar Analyst Report - Watson Pharmaceuticals Inc .

      Stock Reports

      Mon, 17 Sep 2012

      with shareholder interests, in our opinion. Upon closing of the recently announced Actavis acquisition, Watson Pharmaceuticals will become the third-largest global generic drug manufacturer. Post merger, international sales will represent

    5. Lose The Swimmies!


      Fri, 7 Sep 2012

      Pharmaceuticals declined despite reporting earnings above expectations, and a resolution of pending litigation with Watson Pharmaceuticals regarding Endo’s Lidoderm. Investors are concerned about the potential for generic competition for Endo’s flagship

    6. Endo Sees Strong Generics Demand in 2Q


      Tue, 7 Aug 2012

      the firm’s former flagship product beginning in late 2013, which is the earliest that generic drugmaker Watson Pharmaceuticals WPI will be able to launch its authorized generic version of the pain patch. We think Opana ER could help offset

    7. TEXT-Fitch rates Watson Pharmaceuticals


      Wed, 27 Jun 2012

      June 27 - Fitch Ratings has assigned a 'BBB' rating to Watson Pharmaceuticals , Inc .'s (Watson) (NYSE: WPI) new five-year senior unsecured term loan facility with an aggregate principal amount of $1

    8. Shire's Citizen Petition No Longer Blocking Generic Adderall XR; No Impact on Our Valuation


      Mon, 25 Jun 2012

      or ANDA, for a generic version of the drug filed by Actavis (which is in the process of being acquired by Watson Pharmaceuticals WPI ). Shire previously authorized two branded generic versions of Adderall XR, through Teva TEVA and Impax

    9. Endo Settles Lidoderm Patent Suit with Watson, Removes Uncertainty Surrounding Fate of Key Product


      Tue, 29 May 2012

      Endo Pharmaceuticals ENDP announced that it has reached an agreement with generic drugmaker Watson Pharmaceuticals WPI regarding marketing exclusivity for its pain patch Lidoderm. The settlement removes a great deal of uncertainty surrounding the

    10. New Product Launches Sustain Surge in Watson's Revenue and Earnings


      Mon, 30 Apr 2012

      Watson Pharmaceuticals WPI reported first-quarter results that mostly met our expectations. However, as a result of the Actavis acquisition announced

    « Prev12345Next »
    Content Partners